肝细胞癌放射栓塞:应答者生存改善的统计学确认(里程碑分析)
研究纳入134例Child-Pugh≤B7且单发肝细胞癌患者,接受放射栓塞治疗,用EASL和RECIST 1.1标准评估影像应答,通过里程碑分析判断应答与总生存的关系。结果显示应答者生存更长,EASL坏死标准优于RECIST 1.1尺寸标准。
要点
- 在3个月里程碑点,EASL应答者生存长于无应答者(HR 0.46),RECIST 1.1未达显著(HR 0.70)。
- 在6个月和12个月里程碑点,EASL和RECIST 1.1应答者生存均长于无应答者。
- EASL坏死标准在预测生存方面优于RECIST 1.1尺寸标准。
核心结论
- 单发肝细胞癌患者放射栓塞后的影像应答可预测生存改善。
- EASL坏死标准在预测生存方面优于RECIST 1.1尺寸标准。
- 放射栓塞的治疗目标应为影像学应答,而不仅是阻止进展。
研究设计与样本
- 回顾性分析14年间948例接受放射栓塞的肝细胞癌患者,排除基线转移、血管侵犯、多发病灶、Child-Pugh>B7及移植/切除者后,纳入134例Child-Pugh≤B7且单发肝细胞癌的均质队列。
- 共复习960份扫描,采用EASL和RECIST 1.1标准评估应答,使用里程碑分析和死亡风险方法分析应答与生存的关系。
- 在每个里程碑点进行单因素和多因素生存分析,并比较应答者与稳定疾病(SD)和进展性疾病(PD)患者的生存时间。
主要发现
- 3个月里程碑点:EASL应答者生存长于无应答者(HR 0.46;CI 0.26-0.82;P=0.002),RECIST 1.1应答者与无应答者无显著差异(HR 0.70;CI 0.37-1.32;P=0.32)。
- 6个月里程碑点:EASL应答者生存长于无应答者(HR 0.32;CI 0.15-0.77;P<0.001),RECIST 1.1应答者生存长于无应答者(HR 0.50;CI 0.29-0.87;P=0.021)。
- 12个月里程碑点:EASL应答者生存长于无应答者(HR 0.34;CI 0.15-0.77;P<0.001),RECIST 1.1应答者生存长于无应答者(HR 0.52;CI 0.27-0.98;P=0.049)。
- 6个月时,EASL应答者死亡风险更低(P<0.001),RECIST 1.1应答者死亡风险更低(P=0.0445)。
- 亚组分析中,应答者生存长于SD或PD患者;EASL应答在3、6、12个月里程碑点的单因素和多因素分析中均为显著的生存预测因素。
临床怎么用
- 作者认为放射栓塞的治疗目标应为影像学应答,而不仅是阻止进展。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Does imaging response predict survival in hepatocellular carcinoma (HCC)? We studied the ability of posttherapeutic imaging response to predict overall survival. Over 14 years, 948 patients with HCC were treated with radioembolization. Patients with baseline metastases, vascular invasion, multifocal disease, Child-Pugh > B7, and transplanted/resected were excluded. This created our homogeneous study cohort of 134 patients with Child-Pugh ≤ B7 and solitary HCC. Response (using European Association for Study of the Liver [EASL] and Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1] criteria) was associated with survival using Landmark and risk-of-death methodologies after reviewing 960 scans. In a subanalysis, survival times of responders were compared to those of patients with stable disease (SD) and progressive disease (PD). Uni/multivariate survival analyses were performed at each Landmark. At the 3-month Landmark, responders survived longer than nonresponders by EASL (hazard ratio [HR], 0.46; confidence interval [CI], 0.26-0.82; P = 0.002) but not RECIST 1.1 criteria (HR, 0.70; CI, 0.37-1.32; P = 0.32). At the 6-month Landmark, responders survived longer than nonresponders by EASL (HR, 0.32; CI, 0.15-0.77; P < 0.001) and RECIST 1.1 criteria (HR, 0.50; CI, 0.29-0.87; P = 0.021). At the 12-month Landmark, responders survived longer than nonresponders by EASL (HR, 0.34; CI, 0.15-0.77; P < 0.001) and RECIST 1.1 criteria (HR, 0.52; CI 0.27-0.98; P = 0.049). At 6 months, risk of death was lower for responders by EASL (P < 0.001) and RECIST 1.1 (P = 0.0445). In subanalyses, responders lived longer than patients with SD or PD. EASL response was a significant predictor of survival at 3-, 6-, and 12-month Landmarks on uni/multivariate analyses. CONCLUSION: Response to radioembolization in patients with solitary HCC can prognosticate improved survival. EASL necrosis criteria outperformed RECIST 1.1 size criteria in predicting survival. The therapeutic objective of radioembolization should be radiologic response and not solely to prevent progression. (Hepatology 2018;67:873-883).
引用
- Riaz A, Gabr A, Abouchaleh N, et al. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. Hepatology. 2018. PMID: 28833344. doi:10.1002/hep.29480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。